Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hurst

Showing results (231-240 of 276) with videos related to

Pageof 28
Sort By:
Bioorganic & Medicinal Chemistry|December 8, 2004
Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonistsJohn W Huffman, Gulay Zengin, Ming-Jung Wu, et al.
Computers in Biology and Medicine|October 10, 2025
Use of Bayesian decision analysis in the design of patient-centered clinical trials for kidney failure devicesZied Ben Chaouch, Qingyang Xu, Shomesh E Chaudhuri, et al.
Plos One|April 30, 2020
Pneumococcal colonization prevalence and density among Thai children with severe pneumonia and community controlsBarameht Piralam, Christine Prosperi, Somsak Thamthitiwat, et al.
Journal of Medical Internet Research|November 24, 2023
Venous Access: National Guideline and Registry Development (VANGUARD): Advancing Patient-Centered Venous Access Care Through the Development of a National Coordinated Registry NetworkAndrea Iorga, Marti J Velezis, Danica Marinac-Dabic, et al.
Chemmedchem|February 4, 2012
Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive propertiesJose Cumella, Laura Hernández-Folgado, Rocio Girón, et al.
Environmental Toxicology and Pharmacology|July 26, 2011
Risk assessment and management of new and existing chemicalsC J Van Leeuwen, F Bro-Rasmussen, T C Feijtel, et al.
Bioorganic & Medicinal Chemistry Letters|February 27, 2016
Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-onesMaria Elena Meza-Aviña, Mary A Lingerfelt, Linda M Console-Bram, et al.
Biochemistry|November 27, 2013
Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligandsEvangelia Kotsikorou, Haleli Sharir, Derek M Shore, et al.
Kidney360|August 3, 2022
Development of a Patient Preference Survey for Wearable Kidney Replacement Therapy DevicesJennifer E Flythe, Derek Forfang, Nieltje Gedney, et al.
Journal of Medicinal Chemistry|April 7, 2021
Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma EfficacySumanta Garai, Luciana M Leo, Anna-Maria Szczesniak, et al.
Pageof 28

Showing results (231-240 of 276) with videos related to

Sort By:
Pageof 28
Bioorganic & Medicinal Chemistry|December 8, 2004
Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonistsJohn W Huffman, Gulay Zengin, Ming-Jung Wu, et al.
Computers in Biology and Medicine|October 10, 2025
Use of Bayesian decision analysis in the design of patient-centered clinical trials for kidney failure devicesZied Ben Chaouch, Qingyang Xu, Shomesh E Chaudhuri, et al.
Plos One|April 30, 2020
Pneumococcal colonization prevalence and density among Thai children with severe pneumonia and community controlsBarameht Piralam, Christine Prosperi, Somsak Thamthitiwat, et al.
Journal of Medical Internet Research|November 24, 2023
Venous Access: National Guideline and Registry Development (VANGUARD): Advancing Patient-Centered Venous Access Care Through the Development of a National Coordinated Registry NetworkAndrea Iorga, Marti J Velezis, Danica Marinac-Dabic, et al.
Chemmedchem|February 4, 2012
Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive propertiesJose Cumella, Laura Hernández-Folgado, Rocio Girón, et al.
Environmental Toxicology and Pharmacology|July 26, 2011
Risk assessment and management of new and existing chemicalsC J Van Leeuwen, F Bro-Rasmussen, T C Feijtel, et al.
Bioorganic & Medicinal Chemistry Letters|February 27, 2016
Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-onesMaria Elena Meza-Aviña, Mary A Lingerfelt, Linda M Console-Bram, et al.
Biochemistry|November 27, 2013
Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligandsEvangelia Kotsikorou, Haleli Sharir, Derek M Shore, et al.
Kidney360|August 3, 2022
Development of a Patient Preference Survey for Wearable Kidney Replacement Therapy DevicesJennifer E Flythe, Derek Forfang, Nieltje Gedney, et al.
Journal of Medicinal Chemistry|April 7, 2021
Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma EfficacySumanta Garai, Luciana M Leo, Anna-Maria Szczesniak, et al.
Pageof 28